

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM829491

SUBMISSION TYPE:	NEW ASSIGNMENT		
NATURE OF CONVEYANCE:	RELEASE OF SECURITY INTEREST		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
MIDCAP FINANICAL TRUST, AS AGENT		08/02/2023	a Delaware statutory trust: DELAWARE
RECEIVING PARTY DATA			
Name:	OCULAR THERAPEUTIX, INC.		
Street Address:	24 Crosby Drive		
City:	Bedford		
State/Country:	MASSACHUSETTS		
Postal Code:	01730		
Entity Type:	Corporation: DELAWARE		
PROPERTY NUMBERS Total: 4			
Property Type	Number	Word Mark	
Registration Number:	4135965	RESURE	
Serial Number:	86425297	DEXTENZA	
Serial Number:	87864954	DEXTENZA	
Serial Number:	88068409	PAXTRAVA	
CORRESPONDENCE DATA			
Fax Number:	2028427899		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	12027762046		
Email:	jmfitzpatrick@cooley.com		
Correspondent Name:	JENNIFER FITZPATRICK		
Address Line 1:	C/O COOLEY LLP		
Address Line 2:	1299 Pennsylvania Avenue, NW, Suite 700		
Address Line 4:	WASHINGTON, D.C. 20004		
ATTORNEY DOCKET NUMBER:	350388.101		
NAME OF SUBMITTER:	JENNIFER FITZPATRICK		
SIGNATURE:	/JENNIFER FITZPATRICK/		
DATE SIGNED:	08/04/2023		
Total Attachments: 11			

CH \$115.00 4135965

source=MidCap IP release#page1.tif
source=MidCap IP release#page2.tif
source=MidCap IP release#page3.tif
source=MidCap IP release#page4.tif
source=MidCap IP release#page5.tif
source=MidCap IP release#page6.tif
source=MidCap IP release#page7.tif
source=MidCap IP release#page8.tif
source=MidCap IP release#page9.tif
source=MidCap IP release#page10.tif
source=MidCap IP release#page11.tif

RELEASE OF INTELLECTUAL PROPERTY SECURITY INTEREST

This Release of Intellectual Property Security Interest, dated as of August 2, 2023 (this “**IP Release**”), is made by **MIDCAP FINANCIAL TRUST**, a Delaware statutory trust, as agent (“**Agent**”) for the Lenders, with its principal place of business located at 7255 Woodmont Ave., Suite 200, Bethesda, Maryland 20814, in favor of **OCULAR THERAPEUTIX, INC.**, a Delaware corporation (the “**Grantor**”) with its principal place of business located at 24 Crosby Drive, Bedford, Massachusetts 01730, as follows:

WHEREAS, pursuant to that certain Intellectual Property Security Agreement, dated as of December 21, 2018 (as the same may have been amended, modified, restated, replaced or supplemented from time to time, the “**Original IP Security Agreement**”) recorded with the United States Patent and Trademark Office on December 21, 2018 at Reel/Frame No. 6508/0009 (Trademarks) and on December 21, 2018 at Reel/Frame No. 047845/0171 (Patents) and that certain Amended and Restated Intellectual Property Security Agreement, dated as of June 4, 2021 (as the same may have been amended, modified, restated, replaced or supplemented from time to time, the “**AR IP Security Agreement**” together with the Original IP Security Agreement, the “**IP Security Agreement**”; capitalized terms used herein have the definition provided for in the IP Security Agreement), recorded with the United States Patent and Trademark Office on June 4, 2021 at Reel/Frame No. 7317/0033 (Trademarks) and on June 4, 2021 at Reel/Frame No. 057254/0290 (Patents) wherein Grantor granted to Agent, on behalf of the Lenders, a security interest in and to all of its right, title and interest in all of Grantor’s intellectual property, including those listed on Exhibit A through D thereto;

WHEREAS, the Grantor has requested that Agent release its security interest in and to the patent assets as more particularly described on Schedule A attached hereto (the “**Released Patents**”).

WHEREAS, the Grantor has requested that Agent release its security interest in and to the trademark assets as more particularly described on Schedule B attached hereto (the “**Released Trademarks**”).

WHEREAS, the Grantor has requested that Agent release its security interest in and to the various intellectual property assets set forth in Sections (a) through (j) of the IP Security Agreement (together with the Released Patents and Released Trademarks, the “**Released IP Collateral**”).

NOW, THEREFORE, Agent, without recourse, representation or warranty and at Grantor’s sole cost and expense, hereby releases all of its right, title and interest in and to the Released IP Collateral.

[SIGNATURE PAGE FOLLOWS]


IN WITNESS WHEREOF, Agent has caused this IP Release to be duly executed and delivered by its duly authorized officer as of the date first written above.

AGENT:

MIDCAP FINANCIAL TRUST, a Delaware statutory trust

By: Apollo Capital Management, L.P.,
its investment manager

By: Apollo Capital Management GP, LLC,
its general partner

By:  _____

Name: Maurice Amsellem
Title: Authorized Signatory

Schedule A

Patents

Serial No. (Filing Date) or Pat. No. (Issue Date)	Jurisdiction	Title		Expiration Date
Pat. No. 9,254,267 (02-09-2016)	United States	Composite Hydrogel Drug Delivery Systems	Granted	Expires: 09-11-2024
Ser. No. PCT/US99/18530 (08-13-1999)	PCT	Composite Hydrogel Drug Delivery Systems	Expired	
Pat. No. 2,339,482 (10-20-2009)	Canada	Composite Hydrogel Drug Delivery Systems	Expired	
Pat. No. 4601169 (10-08-2010)	Japan	Composite Hydrogel Drug Delivery Systems	Expired	
Pat. No. 6,566,406 (05-20-2003)	United States	Biocompatible Crosslinked Polymers	Expired	
Pat No. 8,003,705 (08-23-2011)	United States	Biocompatible Hydrogels Made With Small Molecule Precursors	Expired	
Pat No. 8,535,705 (09-17-2013)	United States	Biocompatible Polymers And Hydrogels And Methods Of Use	Granted	Expires: 8-3-2024
Ser. No. PCT/US99/28718 (12-03-1999)	PCT	Biocompatible Crosslinked Polymers	Expired	
Pat No. 2353642 (10-11-2009)	Canada	Biocompatible Crosslinked Polymers	Expired	
Pat No. 6,703,047 (03-09-2004)	United States	Dehydrated Hydrogel Precursor-Based, Tissue Adherent Compositions And Methods Of Use	Expired	
Pat No. 8,512,749 (08-20-2013)	United States	Dehydrated Hydrogel Precursor-Based, Tissue Adherent Compositions And Methods Of Use	Granted	Expires: 3-29-2029
Ser. No. PCT/02/03101 (01-31-2002)	PCT	Dehydrated Hydrogel Precursor-Based, Tissue Adherent Compositions And Methods Of Use	Expired	
Ser. No. PCT/US97/16897 (09-22-1997)	PCT	Methods And Devices For Preparing Protein Concentrates	Expired	
Pat No. 9,125,807 (09-08-2015)	United States	Hydrogel Polymeric Compositions And Methods	Granted	Expires: 7-22-2028
Pat No. 9,775,906 (10-03-2017)	United States	Hydrogel Polymeric Compositions And Methods	Granted	Expires: 7-09-2027
Pat No. 9,370,485 (06-21-2016)	United States	Hydrogel Polymeric Compositions And Methods	Granted	Expires: 7-09-2027
Pat. No. 10,251,954 (04-09-2019)	United States	Hydrogel Polymeric Compositions And Methods	Granted	Expires: 7-09-2027

Serial No. (Filing Date) or Pat. No. (Issue Date)	Jurisdiction	Title		Expiration Date
Ser. No. PCT/US2008/006 114 (05-14-2008)	PCT	Hydrogel Polymeric Compositions And Methods	Expired	
Pat No. 2008275786 (1-30-2014)	Australia	Hydrogel Polymeric Compositions And Methods	Granted	Expires: 5-14-2028
Ser. No. 08754416.9 (05-14-2008)	European Patent Office	Hydrogel Polymeric Compositions And Methods	Pending	
Pat No. 5693954 (02-13-2015)	Japan	Hydrogel Polymeric Compositions And Methods	Granted	Expires: 5-14-2028
Pat No. 8,409,606 (04-02-2013)	United States	Drug Delivery Through Hydrogel Plugs	Granted	Expires: 5-14-2030
Pat No. 8,563,027 (10-22-2013)	United States	Drug Delivery Through Hydrogel Plugs	Granted	Expires: 2-12-2030
Ser. No. PCT/US2010/024 029 (02-12-2010)	PCT	Drug Delivery Through Hydrogel Plugs	Expired	
Pat No. 2010213612 (08-13-2015)	Australia	Drug Delivery Through Hydrogel Plugs	Granted	Expires: 2-12-2030
Pat No. 2750242 (05-22-2018)	Canada	Drug Delivery Through Hydrogel Plugs	Granted	Expires: 2-12-2030
Pat No. ZL201080016295. 1 (08-19-2015)	China	Drug Delivery Through Hydrogel Plugs	Granted	Expires: 2-12-2030
Ser. No. 10741771.9 (02-12-2010)	European Patent Office	Drug Delivery Through Hydrogel Plugs	Pending	
Ser. No. 6272/DELNP/201 1 (02-12-2010)	India	Drug Delivery Through Hydrogel Plugs	Pending	
Pat No. 5890182 (02-26-2016)	Japan	Drug Delivery Through Hydrogel Plugs	Granted	Expires: 2-12-2030
Pat No. 8,961,501 (02-24-2015)	United States	Method For Applying Flowable Hydrogels To A Cornea	Granted	Expires: 10-8-2032
Pat. No. 10,226,417 (03-12-2019)	United States	Drug Delivery Systems and Applications	Granted	Expires: 4-30-2032
Ser. No. 16/203,782 (11-29-2018)	United States	Drug Delivery Systems and Applications	Pending	
Pat No. 9,205,150 (12-08-2015)	United States	Medical Organogel Processes And Compositions	Granted	Expires: 04-17-2033

Serial No. (Filing Date) or Pat. No. (Issue Date)	Jurisdiction	Title		Expiration Date
Ser. No. 14/926,707 (10-29-2015)	United States	Medical Organogel Processes And Compositions	Pending	
Ser. No. PCT/US2012/067 978 (12-18-2012)	PCT	Medical Organogel Processes And Compositions	Expired	
Pat No. 2012347926 (06-28-2018)	Australia	Medical Organogel Processes And Compositions	Granted	Expires: 12-5-2032
Pat. No. 2,858,161 (03-10-2020)	Canada	Medical Organogel Processes And Compositions	Granted	Expires: 12-5-2032
Pat No. ZL201280073745. X (10-09-2018)	China	Medical Organogel Processes And Compositions	Granted	Expires: 12-5-2032
Ser. No. 201811049910.3 (09-10-2018)	China	Medical Organogel Processes And Compositions	Pending	
Pat. No. 1203367B (11-08-2019)	Hong Kong	Medical Organogel Processes And Compositions	Granted	Expires: 12-5-2032
Pat. No. 2787973 (10-09-2019)	European Patent Office	Medical Organogel Processes And Compositions	Granted	Expires: 12-5-2032
Pat. No. 345247 (08-27-2020)	India	Medical Organogel Processes And Compositions	Granted	Expires: 12-5-2032
Pat No. 6199883 (09-01-2017)	Japan	Medical Organogel Processes And Compositions	Granted	Expires: 12-5-2032
Pat. No. 10-2039468 (10-28-2019)	Korea	Medical Organogel Processes And Compositions	Granted	Expires: 12-5-2032
Ser. No. 14/965,258 (12-10-2015)	United States	Hydrogel Drug Delivery Implants	Pending	
Ser. No. PCT/US2015/064 975 (12-10-2015)	PCT	Hydrogel Drug Delivery Implants	Expired	
Ser. No. 2015360469 (12-10-2015)	Australia	Hydrogel Drug Delivery Implants	Pending	
Ser. No. 2,969,716 (12-10-2015)	Canada	Hydrogel Drug Delivery Implants	Pending	
Ser. No. 201580075658.1 (12-10-2015)	China	Hydrogel Drug Delivery Implants	Pending	
Pat. No. 3229779 (2-3-2021)	European Patent Office	Hydrogel Drug Delivery Implants	Granted	Expires: 12-10-2035

Serial No. (Filing Date) or Pat. No. (Issue Date)	Jurisdiction	Title		Expiration Date
Ser. No. 201717019261 (12-10-2015)	India	Hydrogel Drug Delivery Implants	Pending	
Ser. No. 2017- 531184 (12-10-2015)	Japan	Hydrogel Drug Delivery Implants	Pending	
Ser. No. 10-2017- 7018919 (12-10-2015)	Korea	Hydrogel Drug Delivery Implants	Pending	
Ser. No. 14/878,243 (10-08-2015)	United States	Ocular Gels Or Hydrogels And Microinjectors	Pending	
Ser. No. 15/152,739 (05-12-2016)	United States	Drug Delivery From Hydrogels	Pending	
Ser. No. PCT/US2016/032 046 (05-12-2016)	PCT	Drug Delivery From Hydrogels	Expired	
Pat. No. 2016261925 (01-14-2021)	Australia	Drug Delivery From Hydrogels	Granted	Expires: 5-12-2036
Ser. No. 2,985,656 (05-12-2016)	Canada	Drug Delivery From Hydrogels	Pending	
Ser. No. 16793509.7 (05-12-2016)	European Patent Office	Drug Delivery From Hydrogels	Pending	
Ser. No. 18112166.3 (09-30-2018)	Hong Kong	Drug Delivery From Hydrogels	Pending	
Ser. No. 2017- 559083 (05-12-2016)	Japan	Drug Delivery From Hydrogels	Pending	
Pat. No. 10,617,563 (04-14-2020)	United States	Coated Implants	Granted	Expires: 7-22-2036
Ser. No. PCT/US2016/043 647 (07-22-2016)	PCT	Coated Punctal Plug	Expired	
Ser. No. 2016297642 (7-22-2016)	Australia	Coated Punctal Plug	Pending	
Ser. No. 2,993,182 (07-22-2016)	Canada	Coated Punctal Plug	Pending	
Ser. No. 201680051706.8 (07-22-2016)	China	Coated Punctal Plug	Pending	

Serial No. (Filing Date) or Pat. No. (Issue Date)	Jurisdiction	Title		Expiration Date
Ser. No. 18112728.4 (10-05-2018)	China/Hong Kong	Coated Punctal Plug	Pending	
Ser. No. 16747681.1 (07-22-2016)	European Patent Office	Coated Punctal Plug	Pending	
Ser. No. 2018- 502739 (07-22-2016)	Japan	Coated Punctal Plug	Pending	
Ser. No. 10-2018- 7005313 (07-22-2016)	Korea	Coated Punctal Plug	Pending	
Ser. No. 15/360,430 (11-23-2016)	United States	Shape Changing Drug Delivery Devices and Methods	Granted	Expires: 11-23-2036
Ser. No. PCT/US2016/063 633 (11-23-2016)	PCT	Shape Changing Drug Delivery Devices and Methods	Expired	
Ser. No. 2016361579 (11-23-2016)	Australia	Shape Changing Drug Delivery Devices and Methods	Pending	
Ser. No. 1120180106712 (11-23-2016)	Brazil	Shape Changing Drug Delivery Devices and Methods	Pending	
Ser. No. 3,006,303 (11-23-2016)	Canada	Shape Changing Drug Delivery Devices and Methods	Pending	
Ser. No. 201680078805.5 (11-23-2016)	China	Shape Changing Drug Delivery Devices and Methods	Pending	
Ser. No. 16816493.7 (11-23-2016)	European Patent Office	Shape Changing Drug Delivery Devices and Methods	Pending	
Ser. No. 259530 (11-23-2016)	Israel	Shape Changing Drug Delivery Devices and Methods	Pending	
Ser. No. 201817020056 (11-23-2016)	India	Shape Changing Drug Delivery Devices and Methods	Pending	
Ser. No. 2018-526903 (11-23-2016)	Japan	Shape Changing Drug Delivery Devices and Methods	Pending	
Ser. No. 10-2018-7017686 (11-23-2016)	Korea	Shape Changing Drug Delivery Devices and Methods	Pending	
Ser. No. 15/714,633 (09-25-2017)	United States	Intracameral Drug Delivery Depots	Pending	
Ser. No. PCT/US2017/053 271 (09-25-2017)	PCT	Intracameral Drug Delivery Depots	Expired	

Serial No. (Filing Date) or Pat. No. (Issue Date)	Jurisdiction	Title		Expiration Date
Ser. No. 2017331444 (09-25-2017)	Australia	Intracameral Drug Delivery Depots	Pending	
Ser. No. 1120190055940 (08-13-2019)	Brazil	Intracameral Drug Delivery Depots	Pending	
Ser. No. 3,038,075 (09-25-2017)	Canada	Intracameral Drug Delivery Depots	Pending	
Ser. No. CN109982683 (07-05-2019)	China	Intracameral Drug Delivery Depots	Pending	
Ser. No. 3515406 (07-31-2019)	European Patent Office	Intracameral Drug Delivery Depots	Pending	
Ser. No. 265421 (09-25-2017)	Israel	Intracameral Drug Delivery Depots	Pending	
Ser. No. 201917015053 (07-19-2019)	India	Intracameral Drug Delivery Depots	Pending	
Ser. No. 2019-529455 (10-17-2019)	Japan	Intracameral Drug Delivery Depots	Pending	
Ser. No. 10-2019-7011614 (09-25-2017)	Korea	Intracameral Drug Delivery Depots	Pending	

PATENT APPLICATIONS

Serial No. (Filing Date) or Pat. No. (Issue Date)	Jurisdiction	Title		Expiration Date
63/106,276 (10-27-2020)	United States	Ocular Implant Containing A Tyrosine Kinase Inhibitor	Pending	
63/106,270 (10-27-2020)	United States	Ocular Implant Containing An Active Agent	Pending	
63/124,176 (12-11-2020)	United States	Intracanalicular Insert Containing A Glucocorticoid	Pending	
63/124,204 (12-11-2020)	United States	Sustained Release Biodegradable Intracanalicular Inserts Comprising A Hydrogel And Cyclosporine	Pending	
63/124,229 (12-11-2020)	United States	Sustained Release Biodegradable Intracanalicular Inserts Comprising A Hydrogel And An Active Agent	Pending	
63/128,565 (12-21-2020)	United States	Methods Of Treating Allergic Conjunctivitis	Pending	
63/136,305 (1-12-2021)	United States	Method Of Treating Ocular Diseases In Human Subjects With Intracameral Implants	Pending	

Serial No. (Filing Date) or Pat. No. (Issue Date)	Jurisdiction	Title		Expiration Date
63/153,316 (2-24-2021)	United States	Intracanalicular Insert Applicator Device	Pending	
63/139,123 (1-19-2021)	United States	Method Of Treating Ocular Diseases In Human Subjects With Intracameral Implants	Pending	
15/766,647 (4-6-2018)	United States	Punctal Plug And Bioadhesives	Published	
17/169,020 (2-5-2021)	United States	Compositions And Methods For Treating Ocular Diseases	Pending	
PCT/US21/16889 (2-5-2021)	PCT	Compositions And Methods For Treating Ocular Diseases	Pending	
		Compositions And Methods For Treating Ocular Diseases	Proposed	
110104830 (2-8-2021)	Taiwan	Compositions And Methods For Treating Ocular Diseases	Pending	
62/838,796 (4-25-2019)	United States	Ocular Hydrogel Tyrosine Kinase Inhibitor Implants	Expired	
62/838,998 (4-26-2019)	United States	Ocular Hydrogel Tyrosine Kinase Inhibitor Implants	Expired	
62/994,391 (3-25-2020)	United States	Ocular Hydrogel Tyrosine Kinase Inhibitor Implants	Expired	
16/857,463 (4-24-2020)	United States	Ocular Hydrogel Tyrosine Kinase Inhibitor Implants	Published	
PCT/US20/29827 (4-24-2020)	PCT	Ocular Hydrogel Tyrosine Kinase Inhibitor Implants	Published	
62/838,739 (4-25-2019)	United States	Compositions For Delivery Of Proteins To The Eye And Methods Of Preparing Same	Expired	
62/838,789 (4-25-2019)	United States	Intracanalicular Hydrogel Inserts For The Delivery Of Anesthetics	Expired	
16/857,458 (4-24-2020)	United States	Intracanalicular Hydrogel Inserts For The Delivery Of Anesthetics	Published	
PCT/US20/29735 (4-24-2020)	PCT	Intracanalicular Hydrogel Inserts For The Delivery Of Anesthetics	Published	
62/838,791 (4-25-2019)	United States	Hydrogel Implants For Lowering Intraocular Pressure	Expired	
62/840,134 (4-29-2019)	United States	Hydrogel Implants For Lowering Intraocular Pressure	Expired	
62/970,828 (2-6-2020)	United States	Hydrogel Implants For Lowering Intraocular Pressure	Expired	
16/857,464 (4-24-2020)	United States	Hydrogel Implants For Lowering Intraocular Pressure	Published	
PCT/US20/29830 (4-24-2020)	PCT	Hydrogel Implants For Lowering Intraocular Pressure	Published	
62/850,125 (5-20-2019)	United States	Hydrogel Inserts For Lowering Intraocular Pressure	Expired	

Serial No. (Filing Date) or Pat. No. (Issue Date)	Jurisdiction	Title		Expiration Date
63/016,030 (4-27-2020)	United States	Dexamethasone Ophthalmic Inserts For Use In The Treating Allergic Conjunctivitis And Related Conditions	Pending	
63/052,646 (7-16-2020)	United States	Dexamethasone Intracanalicular Inserts For The Treatment Of Dry Eye	Pending	
63/082,505 (9-24-2020)	United States	Hydrogel Compositions Comprising Cyclosporine And Uses Thereof	Pending	
63/148,463 (2-11-2021)	United States	Ocular Implant Containing A Tyrosine Kinase Inhibitor	Pending	
PCT/US21/23806 (3-24-2021)	PCT	Ocular Implant Containing A Tyrosine Kinase Inhibitor	Pending	
17/210,696 (3-24-2021)	United States	Ocular Implant Containing A Tyrosine Kinase Inhibitor	Pending	
17/210,719 (3-24-2021)	United States	Ocular Implant Containing A Tyrosine Kinase Inhibitor	Pending	
110110719 (3-24-2021)	Taiwan	Ocular Hydrogel Tyrosine Kinase Inhibitor Implants	Pending	
63/165,536 (3-24-2021)	United States	Implant Injector Device	Pending	
63/165,423 (3-24-2021)	United States	Ocular Implant Containing An Active Agent	Pending	

Schedule B

Trademarks

Ref No. (Country)	Trademark	Registration No. (Issue Date)	Status
15-US-01 (United States)	RESURE	4,135,965 (05/01/2012)	Registered.
15-WO-01 (Australia)	RESURE	1 050 699 (08-26-2010)	Protection granted 02/16/11.
15-WO-01 (China)	RESURE	1 050 699 (08-26-2010)	Protection granted 08/08/11.
15-WO-01 (Czech Republic)	RESURE	1 050 699 (08-26-2010)	Protection granted 05/06/11.
15-WO-01 (France)	RESURE	1 050 699 (08-26-2010)	Protection granted.
15-WO-01 (Germany)	RESURE	1 050 699 (08-26-2010)	Protection granted 2-25-11
15-WO-01 (Hungary)	RESURE	1 050 699 (08-26-2010)	Protection granted 06-29-11
15-WO-01 (Italy)	RESURE	1 050 699 (08-26-2010)	Protection granted 08/01/11.
15-WO-01 (Japan)	RESURE	1 050 699 (08-26-2010)	Registered 9-16-11.
15-WO-01 (Korea)	RESURE	1 050 699 (08-26-2010)	Protection granted 9/1/11. Assigned Int'l Reg. No.
15-WO-01 (Poland)	RESURE	1 050 699 (08-26-2010)	Protection granted 03/21/11.
15-WO-01 (Russia)	RESURE	1 050 699 (08-26-2010)	Protection granted 08/29/11.
15-WO-01 (Singapore)	RESURE	1 050 699 (08-26-2010)	Protection granted 01-19-2011.
15-WO-01 (Spain)	RESURE	1 050 699 (08-26-2010)	Protection granted 02-10-11.
15-WO-01 (United Kingdom)	RESURE	1 050 699 (08-26-2010)	Protection granted 01-10-11.
N/A (United States)	DEXTENZA	86425297 (10-16-14)	Protection granted July 2018
N/A (United States)	DEXTENZA	87864954	Filed 04-05-18. Pending.
N/A (United States)	PAXTRAVA	88068409	Filed 08-07-18. Pending.